ReviewFrontiers in endocrinology2026
Multidimensional regulatory architecture of endometrial receptivity and its translational implications for implantation failure.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial receptivity within the window of implantation (WOI) has been increasingly recognized as an independent determinant of pregnancy outcome in assisted reproduction. Persistent recurrent implantation failure (RIF) is observed in a substantial subset of cycles even after transfer of high-quality embryos, which points toward endometrial factors as targets for closer investigation. Mechanistic work has predominantly been confined to individual signaling pathways examined in isolation, and convergence of hormonal, immune, and epigenetic systems on the receptive state remains insufficiently characterized. Structural readouts dominate at the clinical interface, where endometrial thickness and Doppler indices afford limited insight into molecular dynamics. Consistent clinical benefit has not been delivered by transcriptomic-guided transfer strategies across randomized controlled trials. Evidence is synthesized here across three regulatory tiers of receptivity control. The hormonal signaling network centered on the estrogen and progesterone axis is reviewed together with auxiliary endocrine modulators. The immune regulatory network is dissected through uterine natural killer (uNK) cells, regulatory T (Treg) cells, and macrophage phenotypic transitions. The epigenetic layer is addressed at the level of DNA methylation, histone modification, and non-coding RNA activity. Cross-axis coupling is then examined, with leukemia inhibitory factor (LIF) positioned as a convergence node that integrates endocrine input with immune output and chromatin state. Imaging, molecular profiling, and liquid biopsy are each appraised against current evidence. Translational obstacles imposed by the phenotypic heterogeneity of implantation failure are then considered. Receptivity emerges as a product of coordinated multi-tier regulation rather than as the output of any single pathway. Mechanism-informed stratification, integrating mechanistic evidence with multimodal patient data, lies at the next frontier of clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.